Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Clinical trial NCT03625388 · COMPLETED
Trial details
- NCT number
- NCT03625388
- Sponsor
- Hikma Pharmaceuticals LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-05
- Primary completion
- 2023-07-22
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.